雷替曲噻联合羟基喜树碱和顺铂治疗晚期结直肠癌的安全性观察  

A Safety Observation on Raltitrexed Combined with Cisplatin and Hydroxycamptothecine in the Treatment of Advanced Colorectal Cancer

作　　者：樊华[1] 黄新恩[2] 蔡炜宇[2] 江伟[2] 洪专[2] 钱志英[2] 史美琪[2] 沈波[2] 

机构地区：[1]江苏省老年医学研究所,江苏南京210024 [2]江苏省肿瘤医院化疗科,江苏南京210009

出　　处：《中国临床医学》2007年第5期658-659,707,共3页Chinese Journal of Clinical Medicine

基　　金：江苏省人事厅"六大人材高峰"项目

摘　　要：目的:观察雷替曲噻联合羟基喜树碱和顺铂治疗晚期结直肠癌的安全性,探索治疗晚期结直肠癌的有效方法。方法:雷替曲噻3mg.m-2静滴15min,第1天;羟基喜树碱6mg.m-2,静滴第1～5天;顺铂10mg.m-2静滴第1～5天。每3周重复。结果:在6例复治患者中,5例至少进行了2个周期化疗,可评价疗效,其中,部分缓解(PR)1例,微效(MR)1例,稳定(SD)3例。与研究方案相关的毒副反应为:I～Ⅲ度恶心/呕吐3例,腹泻1例,Ⅲ度便秘1例;I度血总胆红素升高和谷丙转氨酶升高各1例;此外还有周围神经毒性1例,表现为早搏的心脏毒性1例。有1例女性患者出现Ⅲ度血小板下降,经治疗后恢复。未见Ⅳ级毒副反应,无治疗相关死亡。结论:雷替曲噻联合羟基喜树碱和顺铂治疗晚期结直肠癌安全性好,值得进一步观察疗效。Objective：To observe the safety of raltitrexed combined with cisplatin and hydroxycamptothecine in the treatment of advanced colorectal cancer. Methods：Six patients with advaned colorectal cancer who received previous regimens containg 5- FU,oxaliplatin or irinotican were treated with raltitrexed 3 mg·m^-2 by intravenous infusion （iv）on day 1 , combined with hydroxycamptothecine 6 mg·m^-2 iv on day 1 to day 5,and cisplatin 10 mg·m^-2（iv） on day 1 to day 5 every 21 days. Results： Frequent reported toxicity was nausea （grade 1 2）, vomiting （grade 1 2）, constipation （1 case with grade 3） and diarrhea （grade 1 ）, other toxicities were thrombocytopenia and liver function impairment （all grade 1 ）. All patients recovered after intensified supportive care. No treatment related-death occurred. Conclusion：Raltitrexed combined with cisplatin and hydroxycamptothecine is safe in the treatment of advanced colorectal cancer. This protocol warrants further observation in terms of its efficacy.

关 键 词：结直肠癌 雷替曲噻 化疗 

分 类 号：R979.1[医药卫生—药品]